Vaccine against respiratory infections: new insights and new vaccine

September 6-8, 2019

Bilbao, Spain

1) Opening symposium: Global picture of vaccine-preventable respiratory infections
   Vaccination to reduce global pneumonia mortality in infants
   Have we made any progress in reduction of RTIs in the elderly
   Surveillance of RTIs in Europe – progress, opportunities and challenges
   Are we satisfied with the current respiratory vaccine panels? The UK as the constant driver for reforms in vaccination program

2) Measles elimination
   Measles in Europe – Progress and challenges
   Available evidence on transmission patterns of measles and age of vaccination
   Why measles has such a huge impact on health?

3) Enforcing implantation of vaccines against respiratory infections: round table about compulsory vaccination

4) Progress in influenza virus infections
   Universal influenza vaccine: reality or fiction?
   How significant is the problem of response blunting due to repeated influenza vaccination
   Prospects for universal childhood influenza vaccination in Europe
   Newer/extended influenza vaccines
5) **Progress in RSV vaccines**
   
   How new technologies can change RSV vaccine development
   
   Improved or long-acting monoclonal preparations against RSV – can they be applied universally
   
   Experimental RSV vaccine in Field studies in children and adults

6) **Vaccination during pregnancy**

   Vaccinating pregnant women to protect against RTI in their offspring – immunological aspect
   
   Vaccinating pregnant women to protect their offspring against RTI – global increase in equity
   
   Pertussis vaccination for pregnant women - success and challenges

7) **Pneumococcal vaccines**

   Human studies – Pneumococcal vaccination, immune response and nasopharyngeal carriage
   
   Closing the gaps in pneumococcal and Hib vaccination for the developing world
   
   The Global Pneumococcal Sequencing project

8) **VZV vaccines**

   Does generalized immunization in infants have an impact on zoster incidence in adults?
   
   Time to make the point of VZV generalized vaccination

9) **Vaccine hesitancy among health care providers: the paradox of hostility**

10) **Appropriate endpoints in RTI vaccine trials: Impact vs. Efficacy**

11) **Prevention of Pertussis – did we reach our limits?**